TABLE 2

Individual Patient Data

Patient	Cohort	Cancer type	EGFR H score	Best response on M11-849 study	Best response on M12-326 study
1	1	Colon	0	Clinically stable	PD
2	1	NSCLC	3	Clinically stable	PD
3	1	HGG	50	Clinically stable	PD
4	1	H&N	12	Clinically stable	PD
5	1	HGG	295	Clinically stable	PD
6	1	Adrenal	0	Clinically stable	SD
7	2	H&N	80	PD	N/A^*
8	2	H&N	235	SD	PR
9	2	Thymoma	115	PD	N/A^*
10	2	Cholangio-carcinoma	55	PD	N/A^*
11	2	NSCLC	278	SD	PD
12	2	Colon	0	SD	PD
13	2	H&N	170	SD	PD
14	2	Cervical	13	PD	N/A^*
15	2	Bladder	228	PD	N/A^*
16	2	H&N	67	PD	N/A^*
17	2	Colon	0	SD	PD
18	2	H&N	32	PD	N/A^*

↵* Patients who had progressive disease at the end of M11-849 study were not eligible for enrolment on the M12-326 extension study.
PD = progressive disease; NSCLC = non–small cell lung cancer; HGG = high-grade glioma; H&N = head and neck; SD = stable disease; N/A = not applicable; PR = partial response.